Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Brand Name | Status | Last Update |
---|---|---|
atomoxetine | ANDA | 2024-02-13 |
atomoxetine hydrochloride | ANDA | 2024-01-09 |
strattera | New Drug Application | 2022-01-06 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | 2 | 15 | 27 | 44 | 23 | 110 |
Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 3 | 1 | 3 | 1 | 8 |
Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 1 | 1 | 2 | 1 | 6 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | — | 2 | 1 | 5 |
Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 3 | — | 1 | — | 4 |
Orthostatic hypotension | D007024 | — | I95.1 | 1 | 1 | — | 1 | — | 3 |
Dyslexia | D004410 | EFO_0005424 | F81.0 | — | — | — | 3 | — | 3 |
Autistic disorder | D001321 | HP_0000717 | F84.0 | — | — | 1 | 2 | — | 3 |
Attention deficit and disruptive behavior disorders | D019958 | HP_0010865 | F91.3 | — | — | 2 | 1 | — | 3 |
Oppositional defiant disorder | D000096865 | — | — | — | — | 2 | 1 | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vasovagal syncope | D019462 | — | R55 | — | 1 | 1 | — | — | 2 |
Fetal alcohol spectrum disorders | D063647 | — | Q86.0 | 1 | — | 1 | — | — | 2 |
Neoplasms | D009369 | — | C80 | — | — | 1 | — | — | 1 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | 1 | — | — | 1 |
Psychiatry | D011570 | — | — | — | — | 1 | — | — | 1 |
Gastrointestinal microbiome | D000069196 | — | — | — | — | 1 | — | — | 1 |
Probiotics | D019936 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 5 | 11 | — | — | — | 11 |
Cocaine-related disorders | D019970 | — | F14 | 2 | 1 | — | — | 2 | 5 |
Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | 1 | 2 |
Orthostatic intolerance | D054971 | — | — | 2 | 1 | — | — | — | 2 |
Down syndrome | D004314 | EFO_0001064 | Q90 | — | 2 | — | — | — | 2 |
Tobacco use disorder | D014029 | — | F17 | 1 | 1 | — | — | 1 | 2 |
Memory disorders | D008569 | — | — | — | 2 | — | — | — | 2 |
Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 2 | — | — | — | 2 |
Tachycardia | D013610 | HP_0001649 | R00.0 | 1 | 1 | — | — | — | 1 |
Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pure autonomic failure | D054970 | — | — | 1 | — | — | — | 1 | 2 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Alcohol-induced disorders | D020751 | — | — | 1 | — | — | — | — | 1 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 2 | 2 |
Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | — | — | — | 1 | 1 |
Multiple system atrophy | D019578 | — | — | — | — | — | — | 1 | 1 |
Parkinsonian disorders | D020734 | HP_0001300 | G20.C | — | — | — | — | 1 | 1 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | — | — | — | 1 | 1 |
Menopause | D008593 | EFO_0003922 | N95 | — | — | — | — | 1 | 1 |
Whiplash injuries | D014911 | — | — | — | — | — | — | 1 | 1 |
Neurofeedback | D058765 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Atomoxetine |
INN | atomoxetine |
Description | Atomoxetine is a secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents. It has a role as an adrenergic uptake inhibitor, an antidepressant, a xenobiotic and an environmental contaminant. It is an aromatic ether, a secondary amino compound and a member of toluenes. |
Classification | Small molecule |
Drug class | antidepressants (fluoxetine type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CNCC[C@@H](Oc1ccccc1C)c1ccccc1 |
PDB | — |
CAS-ID | 83015-26-3 |
RxCUI | — |
ChEMBL ID | CHEMBL641 |
ChEBI ID | 127342 |
PubChem CID | 54841 |
DrugBank | DB00289 |
UNII ID | ASW034S0B8 (ChemIDplus, GSRS) |